

## Antimicrobial Use and Resistance (AUR): Pharmacy Data Monthly Electronic Upload Specification Tables

These data will be collected in an aggregate monthly electronic file transfer from the facility to NHSN via Clinical Document Architecture (CDA).

Table 1. CDA	File Descriptor	<b>S</b> These data elen	nents will be tran	smitted with each mo	nth's report.			
Variable Name	Description	Description of Variable						
orgid	NHSN Fac	NHSN Facility ID number						
location	NHSN loca	NHSN location code						
month	Denominat	ominator month						
year	Denominat	Denominator year						
createDate	••••••	Date the record was created						
createUserID	The user th	ne user that created the record						
version	Version nu	mber of the softwar	e under which	the data was collec	ted			
modifyDate	••••••	Date the record was last updated						
modifyUserID	••••••	The user that last modified record						
modifyVersion	Version nu	Version number of the software under which the data was last updated						
	gate Patient In			are aggregated to the		tv wide innatient leve	I for each month	
Variable Name	Description		data ciements t	are aggregated to the	rocation and racin	ty wide inpatient level	Tor each monan.	
numDaysPrese		Total number of days present						
numTherapyDays Number of therapy days								
numAdmissions Number of admissions								
Harri (arrii33iori)	3 : Number of			nts are obtained from	41 F1116-114			
Table 3. Aggre		Pharmacy Information  (eMAR) or bar coding medication administration (BCMA) and aggregated to the location and facility wide inpatient level for each month.  Description of Variable  Examples						
drugIngredient		Antimicrobial ingredient (see Table 3a)						
routeDrugAdmi		Route of administration Digestive tract, respiratory tract, intravenous route, intramuscular route						
ж		Th		ntimicrobials currently				
	of Antimicrobia		porting.		·	·		
Amantadine	Caspofungin	Cefprozil	Colistimethate	Fidaxomicin	Metronidazole	Peramivir	Telavancin	
Amikacin	Baloxavir marboxil	Ceftaroline	Colistin	Fluconazole	Micafungin	  Piperacillin	Tetracycline	
Amoxicillin	Cefaclor	Ceftazidime	Dalbavancin	Fosfomycin	Minocycline	Piperacillin/ Tazobactam	Tigecycline	
Amoxicillin/	Cciacioi	Ceftazidime/	Daibavarion	1 osioniyoni	Williocyclinic	!	i igeoyenne	
Clavulanate	Cefadroxil	Avibactam	Daptomycin	Gemifloxacin	Moxifloxacin	Plazomicin	Tinidazole	
		Ceftolozane/						
Amphotericin B	Cefazolin	Tazobactam	Delafloxacin	Gentamicin	Nafcillin	Polymyxin B	Tobramycin	
Amphotericin B liposomal	Cefdinir	Ceftriaxone	Dicloxacillin	Imipenem/ Cilastatin	Nitrofurantoin	Posaconazole	Vancomycin	
Προσοιτίαι	Celulilli	Centriaxone	DICIOXACIIIII	Cliasialiii	Omadacycline	Quinupristin/	Vanconiyeni	
Ampicillin	Cefepime	Cefuroxime	Doripenem	Isavuconazonium	Omadacycline	Dalfopristin	Voriconazole	
Ampicillin/						:		
Sulbactam	Cefixime	Cephalexin	Doxycycline	Itraconazole	Oritavancin	Remdesivir	Zanamivir	
Anidulafungin	Cefotaxime	Chloramphenicol	Eravacycline	Levofloxacin	Oseltamivir	Rifampin		
Arikayce	Cefotetan	Ciprofloxacin	Ertapenem	Linezolid	Oxacillin	Rimantadine		
Azithromycin	Cefoxitin	Clarithromycin	Erythromycin	Meropenem	Penicillin G	Sulfamethoxazole/ Trimethoprim		
Aztreonam	Cefpodoxime	Clindamycin	Erythromycin/ Sulfisoxazole	Meropenem/ Vaborbactam	Penicillin V	Tedizolid		
		<del></del>		in this surveillance syst			individual or	

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

Public reporting burden of this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333 ATTN: PRA (0920-0666).

CDC 57.124 v5, 9.4



